Log in

NASDAQ:OMEDOncomed Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.89
0.00 (0.00 %)
(As of 04/23/2019)
Add
Compare
Today's Range
$0.89
Now: $0.89
$0.89
50-Day Range
$0.89
MA: $0.89
$0.89
52-Week Range
$0.55
Now: $0.89
$3.35
Volume1,201 shs
Average Volume768,904 shs
Market Capitalization$34.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.
Read More
Oncomed Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.01 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.42 million
Book Value$1.25 per share

Profitability

Net Income$-8,100,000.00

Miscellaneous

Employees22
Market Cap$34.43 million
Next Earnings DateN/A
OptionableOptionable

Receive OMED News and Ratings via Email

Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter.

Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions

How were Oncomed Pharmaceuticals' earnings last quarter?

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to analysts' expectations of $7.97 million. Oncomed Pharmaceuticals had a negative net margin of 18.24% and a negative return on equity of 13.14%. View Oncomed Pharmaceuticals' earnings history.

Has Oncomed Pharmaceuticals been receiving favorable news coverage?

Media coverage about OMED stock has trended positive recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Oncomed Pharmaceuticals earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutOncomed Pharmaceuticals.

Who are some of Oncomed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oncomed Pharmaceuticals own?

Who are Oncomed Pharmaceuticals' key executives?

Oncomed Pharmaceuticals' management team includes the following people:
  • Mr. Perry A. Karsen, Exec. Chairman (Age 64)
  • Ms. Jill Henrich, Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Ann Kapoun Ph.D., Sr. VP of Translational Medicine

What is Oncomed Pharmaceuticals' stock symbol?

Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

What is Oncomed Pharmaceuticals' stock price today?

One share of OMED stock can currently be purchased for approximately $0.89.

How big of a company is Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals has a market capitalization of $34.43 million and generates $44.42 million in revenue each year. The biopharmaceutical company earns $-8,100,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Oncomed Pharmaceuticals employs 22 workers across the globe.

What is Oncomed Pharmaceuticals' official website?

The official website for Oncomed Pharmaceuticals is www.oncomed.com.

How can I contact Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.